ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "treatment"

  • Abstract Number: 2358 • 2013 ACR/ARHP Annual Meeting

    Sarilumab, a Subcutaneously Administered, Fully Human Monoclonal Antibody Inhibitor Of The IL-6 Receptor Alpha: 12 Week Infection Rates By Level Of Circulating Neutrophils In Rheumatoid Arthritis and Ankylosing Spondylitis

    Kevin L. Winthrop1, Tanya Momtahen2, Stefano Fiore3, Steven P. Weinstein4, Janet van Adelsberg5, Richard Wu6 and Neil Graham7, 1Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, 2Program Direction, Sanofi, Bridgewater, NJ, 3Clinical Science, Sanofi, Bridgewater, NJ, 4Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, 5Clinical Science, Regeneron Pharmaceutials, Inc., Tarrytown, NY, 6BioStatistics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 7Program Direction, Regeneron Pharmaceuticals, Inc., Tarrytown, NY

    Background/Purpose: Sarilumab is a human monoclonal antibody directed against the alpha subunit of the IL-6 receptor (IL-6Rα). IL-6 blockade is associated with a reduction in…
  • Abstract Number: 1418 • 2013 ACR/ARHP Annual Meeting

    Effects Of Smoking Status On Response To Treatment With Tofacitinib In Patients With Rheumatoid Arthritis

    J. M. Kremer1, J. D. Greenberg2, C. Turesson3, D. Gruben4, C. A. Mebus4, E. Bananis5 and T. Robinson6, 1Albany Medical College and The Center for Rheumatology, Albany, NY, 2Rheumatology, NYU Hospital for Joint Diseases, New York, NY, 3Lund University, Malmö, Sweden, 4Pfizer Inc, Groton, CT, 5Specialty Care, Pfizer Inc, Collegeville, PA, 6Pfizer Inc, Collegeville, PA

    Background/Purpose: Cigarette smoking is a known risk factor for developing rheumatoid arthritis (RA).1 Several recent observational studies suggest that cigarette smoking may be associated with…
  • Abstract Number: 443 • 2013 ACR/ARHP Annual Meeting

    Efficacy and Safety Analyses Of Tofacitinib From Pooled Phase 2, Phase 3 and Long-Term Extension Rheumatoid Arthritis Studies: US Compared With Non-US Populations

    S. B. Cohen1, Roy Fleischmann1, J. M. Kremer2, A. Koenig3, K. Kwok4, L. Wang5, C. a. Mebus5, R. Riese5 and T. Robinson3, 1Metroplex Clinical Research Center, Dallas, TX, 2Albany Medical College and The Center for Rheumatology, Albany, NY, 3Pfizer Inc, Collegeville, PA, 4Pfizer Inc, New York, NY, 5Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor approved in the US for the treatment of rheumatoid arthritis at 5 mg BID. Phase (P) 3…
  • Abstract Number: 2331 • 2013 ACR/ARHP Annual Meeting

    Efficacy and Safety Of Tofacitinib In Older and Younger Patients With Rheumatoid Arthritis

    J. R. Curtis1, H. Schulze-Koops2, L Takiya3, C. A. Mebus4, K. Terry4, R. Chew4 and T. V. Jones3, 1Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 2University of Munich, Munich, Germany, 3Pfizer Inc, Collegeville, PA, 4Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). The clinical development program for tofacitinib in RA enrolled ˃500…
  • Abstract Number: 1387 • 2013 ACR/ARHP Annual Meeting

    Reversing Vascular Dysfunction In Rheumatoid Arthritis: Peroxisome Proliferator-Activated Receptor Gamma Agonist Therapy Improves Augmentation Index But Not Endothelial Function

    Michelle J. Ormseth1, Aihua Bian2, Annette M. Oeser2, Andrew Cunningham2, Ayumi Shintani2, S. Bobo Tanner3 and C. Michael Stein4, 1Rheumatology, Vanderbilt Medical Center, Nashville, TN, 2Vanderbilt Medical Center, Nashville, TN, 3Div of Rheumatology & Allergy, Vanderbilt Medical Center, Nashville, TN, 4School of Medicine, Division of Clinical Pharmacology, Vanderbilt Medical Center, Nashville, TN

    Background/Purpose: Rheumatoid arthritis (RA) is associated with insulin resistance and increased cardiovascular (CV) risk. Impaired vascular function, including arterial stiffness and endothelial dysfunction, is associated…
  • Abstract Number: 445 • 2013 ACR/ARHP Annual Meeting

    Post-Hoc Analysis Of Serious Infection Events and Selected Clinical Factors In Rheumatoid Arthritis Patients Treated With Tofacitinib

    J. J. Gomez-Reino1, A. Hazra2, C. Fosser2, S. Menon3, S. H. Zwillich2, R. Riese2 and S. Krishnaswami3, 1Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, 2Pfizer Inc, Groton, CT, 3Clinical Pharmacology, Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is a novel oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Serious infections (requiring hospitalization or parenteral antibiotics; SIEs)…
  • Abstract Number: 2334 • 2013 ACR/ARHP Annual Meeting

    ORAL SCAN: Effects Of The Oral JAK Inhibitor Tofacitinib In Combination With Methotrexate On Patient Reported Outcomes In a 24-Month Phase 3 Trial Of Active Rheumatoid Arthritis

    V. Strand1, D. van der Heijde2, C. a. F. Zerbini3, C. A. Connell4, D. Gruben4, R. Riese4 and G. Wallenstein4, 1Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, 2Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Rheumatology, Centro Paulista de Investigação Clinica, Sao Paulo, Brazil, 4Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Efficacy, inhibition of structural damage, and safety of tofacitinib…
  • Abstract Number: 1391 • 2013 ACR/ARHP Annual Meeting

    Transporters As Drug Gateway Into The Cell For Specific Targeting Of Tyrosine Kinase Signaling Pathway In Rheumatoid Arthritis

    Saliha Harrach1, Christian Schmidt-Lauber2, Bayram Edemir3, Eberhard Schlatter1, Thomas Pap4, Giuliano Ciarimboli1 and Jessica Bertrand2, 1Experimental Nephrology, Medical Clinic und Policlinic D, University Hospital Münster, Münster, Germany, 2Institute of Experimental Musculoskeletal Medicine (IEMM), University Hospital Münster, Münster, Germany, 3Experimental Nephrology, Medical Clinic und Policlinic D, University Hospital Münster, Muenster, Germany, 4Institute of Experimental Muskuloskeletal Medicine, University Hospital Münster, Münster, Germany

    Background/Purpose: Tyrosine kinase inhibitors (TKI) are effective in treating malignant disorders and were suggested to also have an impact on non-malignant diseases such as rheumatoid…
  • Abstract Number: 455 • 2013 ACR/ARHP Annual Meeting

    Oskira-2: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To Disease-Modifying Antirheumatic Drugs

    Peter Dawes1, Aleksandar Dimic2, Mark C. Genovese3, Désiréé van der Heijde4, Martin Jenkins5, Chris O'Brien6, Barry Oemar7, Jiri Vencovsky8 and Michael Weinblatt9, 1Department of Rheumatology, University of North Staffordshire NHS Trust, Stoke-on-Trent, United Kingdom, 2Rheumatology Institute, Niška Banja, Serbia, 3Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, 4Leiden University Medical Center, Leiden, Netherlands, 5AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, 6AstraZeneca R&D Wilmington, Wilmington, DE, 7AstraZeneca R&D Boston, Boston, MA, 8Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Institute of Rheumatology, Prague, Czech Republic, 9Division of Rheumatology, Brigham & Women's Hospital, Boston, MA

    Background/Purpose: Fostamatinib (Fosta) is a novel spleen tyrosine kinase (SYK) inhibitor. The Phase II TASKi studies showed benefit in patients (pts) with active rheumatoid arthritis…
  • Abstract Number: 2336 • 2013 ACR/ARHP Annual Meeting

    Phase 2 Evaluation Of PF-04171327, a Dissociated Agonist Of The Glucocorticoid Receptor, For The Treatment Of Rheumatoid Arthritis In Patients With An Inadequate Response To Methotrexate

    Thomas Stock1, Dona Fleishaker2, Xin Wang2, Arnab Mukherjee2 and Charles Mebus2, 1Pfizer Inc., Collegeville, PA, 2Pfizer Inc., Groton, CT

    Background/Purpose: PF-04171327, a pro drug of PF-00251802, is under investigation as a potential dissociated agonist of the glucocorticoid receptor (DAGR). PF-00251802 is a selective high-affinity…
  • Abstract Number: 1337 • 2013 ACR/ARHP Annual Meeting

    Nearly Pain Free Self-Administration Of Methotrexate Using An Investigational Auto-Injector: Results Of a Phase-2 Clinical Trial In Rheumatoid Arthritis Patients With Mild-To-Severe Functional Limitations

    Alan J. Kivitz1, David McLain2, John Hill3, Bruce Freundlich4, Jonathan Jaffe5 and Kaushik J. Dave6, 1Altoona Center for Clinical Research, Duncansville, PA, 2Rheumatology, McLain Medical Associates, PC, Birmingham, AL, 3Avail Clinical Research, DeLand, FL, 4University of Pennsylvania, Philadelphia, PA, 5Clinical Development, Antares Pharma Inc, Ewing, NJ, 6Product Development, Antares Pharma Inc, Ewing, NJ

    Background/Purpose: Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) treatment. Limitations of systemic exposure of oral MTX can affect its efficacy. Subcutaneous (SC) MTX…
  • Abstract Number: 456 • 2013 ACR/ARHP Annual Meeting

    Oskira-3: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To a Tumor Necrosis Factor -á Antagonist

    Mark Genovese1, Désiréé van der Heijde2, Edward Keystone3, Alberto Spindler4, Claude-Laurent Benhamou5, Arthur Kavanaugh6, Edward Fudman7, Kathy Lampl8, Chris O'Brien8, Emma Duffield9, Jeffrey Poiley10 and Michael Weinblatt11, 1Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, 2Leiden University Medical Center, Leiden, Netherlands, 3University of Toronto, Toronto, ON, Canada, 4Centro Medico Privado de Reumatologia, Tucuman, Argentina, 5Centre Hospitalier Régional d'Orléans, Orleans, France, 6University of California San Diego, San Diego, CA, 7Austin Rheumatology Research PA, Austin, TX, 8AstraZeneca R&D Wilmington, Wilmington, DE, 9AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, 10Arthritis Associates, Orlando, FL, 11Division of Rheumatology, Brigham & Women's Hospital, Boston, MA

    Background/Purpose: Fostamatinib (Fosta) is an oral SYK inhibitor. This 24-wk study (NCT01197755) compared Fosta vs placebo (PBO) on methotrexate (MTX) treatment in patients (pts) with…
  • Abstract Number: 2340 • 2013 ACR/ARHP Annual Meeting

    Persistent Use Of Biologic Therapies At Lower Than Recommended Dosing Among Rheumatoid Arthritis Patients Enrolled In The US Medicare Program

    Jie Zhang1, Fenglong Xie2, Elizabeth S. Delzell3, Huifeng Yun3, James Lewis4, Kevin Haynes5, Lang Chen6, Kenneth G. Saag7 and Jeffrey R. Curtis8, 1Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 3Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 4Medicine, University of Pennsylvania, Philadelphia, PA, 5Clinical Epidemiology and Biostatistics, University of Pennsylvania., Philadelphia, PA, 6Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 7Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, 8University of Alabama at Birmingham, Birmingham, AL

    Title: Persistent Use of Biologic Therapies at Lower Than Recommended Dosing among Rheumatoid Arthritis Patients Enrolled in the US Medicare ProgramBackground/Purpose: Biologic therapy is associated…
  • Abstract Number: 1354 • 2013 ACR/ARHP Annual Meeting

    Successful Self-Administration Of Methotrexate In Rheumatoid Arthritis Patients Using a Prefilled Autoinjector Pen

    Jaime Pachon1, Alan Kivitz2, Kay-Uwe Heuer3 and Uwe Pichlmeier3, 1Arthritis and Rheumatic Care Center, Miami Research Associates, South Miami, FL, 2Altoona Center for Clinical Research, Duncansville, PA, 3medac GmbH, Wedel, Germany

    Background/Purpose:  Methotrexate (MTX) is the most commonly used and recommended DMARD for the treatment of RA. SC administered MTX is well absorbed and appears to…
  • Abstract Number: 459 • 2013 ACR/ARHP Annual Meeting

    Transaminase Levels and Hepatic Events Observed During Tocilizumab Treatment: Pooled Analysis Of Long-Term Clinical Trial Safety Data In Patients With Rheumatoid Arthritis

    MC Genovese1, Joel M. Kremer2, Ronald F. van Vollenhoven3, Rieke Alten4, Juan José Scali5, Ariella Kelman6, Lucy Rowell7 and Laura Pitts7, 1Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, 2Center for Rheumatology, Albany Medical College, Albany, NY, 3Karolinska Institute, Stockholm, Sweden, 4Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, 5Durand University Hospital, Buenos Aires, Argentina, 6Genentech, South San Francisco, CA, 7Roche, Welwyn Garden City, United Kingdom

    Background/Purpose: The interleukin-6 receptor inhibitor tocilizumab (TCZ) has demonstrated efficacy in improving signs/symptoms, reducing joint damage, and improving function and is well tolerated in patients…
  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 22
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology